News - Global, Oncology

Filter

Current filters:

GlobalOncology

Popular Filters

1 to 25 of 36 results

Bayer pays upfront $50 million for Orion’s prostate cancer candidate ODM-201

Bayer pays upfront $50 million for Orion’s prostate cancer candidate ODM-201

02-06-2014

Finland-based drugmaker Orion Corp has entered into a global partnership with German pharma major Bayer…

BayerGlobalLicensingODM-201OncologyOrion CorpPharmaceuticalResearch

Oncology market growth slowing due to fewer breakthroughs and biosimilars, say IMS

06-05-2014

The global oncology drug market reached a value of $91 billion in 2013 but growth in the area is slowing,…

Alternative medicineCancer CareGlobalHealth Medical PharmaIMS HealthOncologyOncologyPharmaceuticalResearch

Clinigen gains rights to SpePharm’s Savene

Clinigen gains rights to SpePharm’s Savene

31-03-2014

The UK’s specialty pharma firm Clinigen Group says it has acquired rights to Savene (dexrazoxane) from…

Clinigen GroupGlobalLicensingNorgineOncologyPharmaceuticalSaveneSpePharma

Nanomedicines market to reach $177.6 billion globally in 2019

08-01-2014

The global market for nanomedicine was valued at $78.54 billion in 2012 and is expected to reach a value…

BiotechnologyCardio-vascularGlobalMarkets & MarketingOncology

Baxter buys exclusive rights to CTI’s cancer drug pacritinib

18-11-2013

USA-based companies Baxter International and Cell Therapeutics have entered into an exclusive worldwide…

Baxter InternationalCell TherapeuticsFinancialGlobalLicensingOncologypacritinibPharmaceutical

Uterine cancer treatments market in need of drugs with high efficacy and safety profiles

18-10-2013

The uterine cancer treatments market has been forecast to increase at a compound annual growth rate (CAGR)…

GlobalMarkets & MarketingOncologyPharmaceutical

Radiopharmaceuticals market to hit a value of $7.9 billion by 2018

21-08-2013

The radiopharmaceuticals market has been forecast to exceed a value of $7.9 billion by 2018, driven by…

Cardio-vascularGlobalMarkets & MarketingNeurologicalOncologyPharmaceutical

B-MS' nivolumab to lead NSCLC market with sales of $1.75 billion by 2022, says GlobalData

08-07-2013

US pharma major Bristol-Myers Squibb's (NYSE: BMY) nivolumab will overtake proven blockbuster competitors…

Bristol-Myers SquibbGlobalMarkets & MarketingnivolumabOncologyPharmaceutical

Cancer treatments "unaffordable" and will drive rapid transition to generics and market decline, says GlobalData

10-05-2013

The rising prices of new cancer drugs are resulting in an increasing cost burden for patients and health…

BiotechnologyGenericsGlobalMarkets & MarketingOncologyPharmaceuticalPricing

Clinigen acquires oncology support therapy Cardioxane from Novartis

26-03-2013

UK-based Clinigen Group (LSE: CLIN) says it has acquired (AIM: CLIN) the oncology support therapy Cardioxane…

CardioxaneClinigen GroupGlobalMergers & AcquisitionsNovartisOncologyPharmaceutical

BRIC countries' breast cancer market to see 8% annual growth to 2017

14-02-2013

The market for breast cancer therapies in the BRIC countries (Brazil, Russia, India and China) will grow…

GlaxoSmithKlineGlobalHerceptinMarkets & MarketingOncologyPharmaceuticalRocheTykerb

Small-molecule cancer drug revenues will reach $32.7 billion in 2016, says Visiongain

09-01-2013

The small-molecule targeted cancer therapy revenues will reach a value of $32.7 billion worldwide in…

BiotechnologyGleevecGlivecGlobalMarkets & MarketingNovartisOncologyPharmaceutical

New drug options for advanced prostate cancer

13-12-2012

Prostate cancer is becoming increasingly common due to globally growing numbers of elderly men, and scientists…

AlpharadinAstellas PharmaBayerGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalXtandiZytiga

Sales of cancer pain therapies set to grow to $5.2 billion in the G7 by 2021

13-12-2012

Sales of cancer pain therapies will increase to $5.2 billion in 2021 in leading seven markets (the USA,…

AmgenBiotechnologyDaiichi SankyodenosumabGlaxoSmithKlineGlobalMarkets & MarketingOncologyPharmaceuticalRanmarkXgeva

NSCLC market will Increase to over $6 billion in 2021, fueled largely by the entry of seven new agents

05-12-2012

The entry of seven new agents into the non-small cell lung cancer (NSCLC) drug market - and in particular…

GlobalMarkets & MarketingOncologyPharmaceuticalResearch

Zeltia's Yondelis approved for sale in 10 new countries

04-12-2012

Pharma Mar, a subsidiary of Spain's Grupo Zeltia (ZEL: MC), says it has been advised by its licensee…

GlobalJanssenJohnson & JohnsonOncologyPharmaceuticalPharmaMarRegulationYondelisZeltia

Prognosis for renal cell carcinoma market development

27-11-2012

Through 2021, small-molecule angiogenesis inhibitors will dominate the renal cell carcinoma (RCC) drug…

Bristol-Myers SquibbGlaxoSmithKlineGlobalMarkets & MarketingnivolumabOncologyPfizerPharmaceuticalSutentVotrient

Prostate cancer drug market will more than double to $9.1 billion in 2021

06-11-2012

The prostate cancer drug market will more than double, increasing from $4.1 billion in 2011 to $9.1 billion…

Astellas PharmaGlobalJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalXtandiZytiga

Generics and biosimilars will lead to decline in colorectal cancer market from $8.3 billion in 2011 to $7.8 billion in 2021

04-11-2012

Through 2021, growth in the market for colorectal cancer (CRC) treatments will decline in the face of…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Biosimilar versions of MAbs for cancer forecast to garner sales of $4.9 billion in 2021

28-10-2012

While branded versions of monoclonal antibodies for cancer are expected to maintain sales of $6.7 million…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Multiple myeloma drug market forecast to reach $7.2 billion in 2021

03-10-2012

The multiple myeloma drug market will experience significant growth, increasing from $4.4 billion in…

BiotechnologyCelgeneGlobalJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRevlimidTakeda PharmaceuticalsVelcade

1 to 25 of 36 results

Back to top